American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS

American Century Companies Inc. boosted its position in Alkermes plc (NASDAQ:ALKS) by 20.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,397,471 shares of the company’s stock after purchasing an additional 740,248 shares during the period. American Century Companies Inc. owned about 2.66% of Alkermes worth $131,924,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. boosted its holdings in shares of Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after buying an additional 747 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Alkermes by 395.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock worth $37,000 after acquiring an additional 989 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Alkermes in the 2nd quarter worth $49,000. Osaic Holdings Inc. raised its holdings in Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock worth $56,000 after purchasing an additional 701 shares during the period. Finally, Bessemer Group Inc. lifted its position in Alkermes by 163.3% during the third quarter. Bessemer Group Inc. now owns 2,222 shares of the company’s stock valued at $67,000 after purchasing an additional 1,378 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALKS. Zacks Research downgraded Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Wells Fargo & Company increased their price objective on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research note on Thursday. Wall Street Zen downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Royal Bank Of Canada dropped their target price on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president owned 57,740 shares of the company’s stock, valued at approximately $1,959,118.20. This trade represents a 13.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares of the company’s stock, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 144,148 shares of company stock valued at $4,911,178 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Key Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Price Performance

NASDAQ ALKS opened at $30.10 on Monday. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $36.32. The business has a 50 day simple moving average of $31.54 and a two-hundred day simple moving average of $30.23. The stock has a market capitalization of $5.02 billion, a PE ratio of 21.05, a P/E/G ratio of 7.51 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. The firm’s revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.